NP-137
- Generic Name
- NP-137
Study of Perioperative NP137 and FOLFIRINOX in Resectable Pancreatic Cancer
- First Posted Date
- 2024-01-12
- Last Posted Date
- 2025-03-10
- Lead Sponsor
- Aram Hezel
- Target Recruit Count
- 25
- Registration Number
- NCT06203821
- Locations
- 🇺🇸
University of Rochester, Rochester, New York, United States
Acute Myeloid Leukemia Treated With With NETrin Abs in Combination With [AZACITIDINE + VENETOCLAX]
Phase 1
Terminated
- Conditions
- Acute Myeloid Leukemia Refractory
- Interventions
- First Posted Date
- 2023-11-29
- Last Posted Date
- 2025-02-20
- Lead Sponsor
- Centre Leon Berard
- Target Recruit Count
- 1
- Registration Number
- NCT06150040
- Locations
- 🇫🇷
Centre Léon Bérard, Lyon, France
NP137 Clinical and Biological Activities Assessment in Patients with Advanced/Metastatic Solid Tumors Treated by Standard Anti PD-1/PD-L1 Immunotherapies
Phase 2
Recruiting
- Conditions
- Advanced Solid TumorsMetastatic Solid Tumors
- Interventions
- Drug: anti-PD-1/PD-L1
- First Posted Date
- 2022-11-04
- Last Posted Date
- 2025-02-14
- Lead Sponsor
- Centre Leon Berard
- Target Recruit Count
- 87
- Registration Number
- NCT05605496
- Locations
- 🇫🇷
Centre Léon Bérard, Lyon, France
🇫🇷Centre Antoine Lacassagne, Nice, France
🇫🇷Institut Curie, Paris, France
Study Investigating the Association of NP137 With Atezolizumab-Bevacizumab Combination in First Line in Unresectable HCC
Phase 1
Recruiting
- Conditions
- Hepatocellular Carcinoma
- Interventions
- First Posted Date
- 2022-09-21
- Last Posted Date
- 2024-03-08
- Lead Sponsor
- University Hospital, Grenoble
- Target Recruit Count
- 52
- Registration Number
- NCT05546879
- Locations
- 🇫🇷
CHU de GRENOBLE ALPES, Grenoble, Alpes, France
Study Investigating the Association of NP137 With mFOLFIRINOX in Locally Advanced Pancreatic Ductal Adenocarcinoma
Phase 1
Active, not recruiting
- Conditions
- Pancreatic Ductal Adenocarcinoma
- Interventions
- First Posted Date
- 2022-09-21
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- University Hospital, Grenoble
- Target Recruit Count
- 43
- Registration Number
- NCT05546853
- Locations
- 🇫🇷
CHU de GRENOBLE ALPES, Grenoble, Alpes, France
🇫🇷CHU de BORDEAUX, Bordeaux, France
🇫🇷CHRU Lille, Lille, France
GYNecological Cancers Treated with NETrin MAbs in Combination with Chemotherapy and /or Pembrolizumab
Phase 1
Active, not recruiting
- Conditions
- Endometrial CarcinomaCervix Carcinoma
- Interventions
- First Posted Date
- 2020-12-03
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- NETRIS Pharma
- Target Recruit Count
- 240
- Registration Number
- NCT04652076
- Locations
- 🇫🇷
Hopital de la Croix Saint Simon, Paris, France
🇫🇷Institut Curie (Site Saint Cloud), Paris, France
🇫🇷Institut Gustave Roussy, Paris, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath